Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVIDFull year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporatio ...

Core Insights - Repligen Corporation has launched three new high-performance chromatography resins, enhancing its proteins portfolio and commitment to innovation in bioprocessing technology [1][2][3] Product Launch - The new products include AVIPure HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, and HiPer™ QA anion exchange resin, which are designed to support gene therapy developers [1][3] - These resins utilize Tantti™ DuloCore™ base bead technology, providing differentiated performance for new modalities such as viral vectors [1] Market Position - Repligen aims to maintain its leadership in process productivity and is preparing for broader chromatography resin launches anticipated in 2026 [2] - The company focuses on delivering scalable, high-performance solutions to meet the needs of gene therapy manufacturers [3] Company Overview - Repligen Corporation is a global life sciences company that specializes in bioprocessing technologies for the manufacturing of biological drugs [4] - The company operates primarily in the areas of Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins, with headquarters in Waltham, Massachusetts [4]